While GAMP 4 claimed to be "risk-based," in practice, it was . Here is the primary criticism:
Before GAMP 4, validation was often a rigid, one-size-fits-all process. GAMP 4 introduced a more structured approach to ensure that software and hardware were .
GAMP 4 assumed the end-user would do most of the testing. It did not adequately emphasize leveraging supplier documentation. This led to duplicate testing—validating features the supplier had already validated. While GAMP 4 claimed to be "risk-based," in practice, it was
Ongoing processes ensure that any changes are formally reviewed so the system remains in a "state of control".
Released in December 2001 by the ISPE (International Society for Pharmaceutical Engineering), GAMP 4 was a landmark document that expanded the scope of validation beyond just manufacturing to include laboratory, clinical, and distribution systems. Evolution and Historical Significance GAMP 4 assumed the end-user would do most of the testing
While it has since been succeeded by (released in 2008), understanding GAMP 4 is essential for professionals dealing with legacy systems, historical compliance data, or the evolution of validation strategies.
| Left Side (Planning & Design) | The Apex | Right Side (Testing & Release) | | :--- | :---: | :--- | | User Requirements Specification (URS) | | User Acceptance Testing (UAT) | | Functional Specification (FS) | | Integration Testing | | Design Specification (DS) | | Module/Unit Testing | | | Build | Code Review / Verification | Ongoing processes ensure that any changes are formally
Many pharmaceutical companies still operate systems validated under GAMP 4. If a company needs to make a change to a system validated in 2003, they must understand the baseline documentation (URS, FS, DS) which follows GAMP 4 standards.